StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
12
This year
1
Publishing Date
2024 - 02 - 26
1
2023 - 09 - 09
1
2023 - 02 - 14
1
2023 - 02 - 02
1
2023 - 01 - 16
1
2022 - 04 - 13
1
2022 - 03 - 15
1
2022 - 02 - 08
1
2021 - 11 - 22
1
2021 - 09 - 20
1
2021 - 03 - 16
1
2020 - 12 - 07
1
Sector
Health technology
12
Tags
Agreement
12
Alliances
22
Antiviral
12
Application
9
Approval
16
Bioscience
10
Biotech
9
Biotech-bay
48
Biotech-beach
11
Breast cancer
22
Cancer
59
Chmp
11
Clinical-trials-phase-iii
14
Collaboration
23
Conference
14
Covid
14
Covid-19
16
Disease
20
Drug
25
Earnings
17
Events
20
Fda
21
Fda-approvals
10
Financial
23
Financial results
20
Genetown
12
Global
35
Growth
10
Health
13
Hepatitis
19
Hiv
41
Impact
9
Leukemia
10
License
13
Liver
11
Market
48
Money
9
N/a
225
People
19
Pharma
12
Pharmaceutical
10
Phase 2
9
Phase 3
9
Positive
13
Potential
10
Pre-clinical
9
Preclinical
10
Report
20
Research
54
Results
51
Sciences
30
Study
11
T-cell
32
Technology
9
Therapeutics
42
Therapy
52
Treatment
50
Trial
23
Trodelvy
15
Yescarta
14
Entities
Abbott laboratories
1
Abbvie inc.
4
Bristol-myers squibb company
5
Cocrystal pharma, inc.
1
Gilead sciences, inc.
12
Glaxosmithkline plc
3
Johnson & johnson
5
Matinas biopharma holdings, inc.
1
Novartis ag
2
Pfizer, inc.
1
Sanofi
2
Teva pharmaceutical industries ltd
1
Tonix pharmaceuticals holding corp.
2
Viatris inc.
2
Vir biotechnology, inc.
1
Symbols
ABBV
8
ABT
2
ABUS
2
ADMP
1
ADTX
5
ALDX
1
ALGS
1
AVIR
5
AYTU
1
BIXT
4
BMY
7
CDTX
1
CMRX
3
COCP
32
EBS
2
ENTA
4
FNCTF
5
GILD
12
GLAXF
5
GSK
6
IGMS
1
IMRN
1
IPIX
2
JNJ
16
LEXX
4
LLY
4
MOLN
1
MRK
14
MTNB
1
NNVC
9
NOVN
2
NVO
1
NVS
3
NVSEF
2
PFE
10
PHIO
1
PVCT
1
RDY
3
RPM
1
SINT
1
SNY
3
SNYNF
3
TAK
1
TEVJF
1
TG
1
TNXP
11
TOMDF
4
TWST
1
VERA
1
VERU
1
VIR
1
VIRI
4
VTRS
2
VXRT
1
Exchanges
Amex
1
Nasdaq
12
Nyse
5
Crawled Date
2024 - 02 - 26
1
2023 - 09 - 09
1
2023 - 02 - 14
1
2023 - 02 - 02
1
2023 - 01 - 16
1
2022 - 04 - 13
1
2022 - 03 - 15
1
2022 - 02 - 08
1
2021 - 11 - 22
1
2021 - 09 - 20
1
2021 - 03 - 16
1
2020 - 12 - 07
1
Crawled Time
04:20
1
11:00
1
12:00
1
13:00
1
14:00
1
14:30
1
15:00
1
16:00
2
17:00
1
20:00
1
23:00
1
Source
www.biospace.com
4
www.globenewswire.com
2
www.prnewswire.com
6
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Antiviral
symbols :
GILD
save search
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
Published:
2024-02-26
(Crawled : 14:30)
- biospace.com/
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
-8.97%
|
O:
-0.07%
H:
0.53%
C:
-0.75%
antiviral
pipeline
research
Oral Antiviral Market Report 2023: Demand for Novel Therapeutics Boosts Opportunities
Published:
2023-09-09
(Crawled : 04:20)
- prnewswire.com
VTRS
|
News
A
|
$11.235
-0.13%
-0.13%
5.1M
|
Health Technology
|
Email alert
Add to watchlist
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
Email alert
Add to watchlist
BMY
|
$49.14
0.43%
0.0%
7.9M
|
Health Technology
|
Email alert
Add to watchlist
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
Email alert
Add to watchlist
ABBV
|
News
|
$167.89
0.89%
0.0%
5.6M
|
Health Technology
|
Email alert
Add to watchlist
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
Email alert
Add to watchlist
TEVJF
|
News
|
$12.37
-24.22%
380
|
Health Technology
|
Email alert
Add to watchlist
JNJ
|
News
|
$149.12
0.82%
0.0%
9.3M
|
Health Technology
|
Email alert
Add to watchlist
report
antiviral
therapeutics
market
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
Published:
2023-02-14
(Crawled : 14:00)
- biospace.com/
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
-23.48%
|
O:
0.11%
H:
0.02%
C:
-2.18%
antiviral
impact
potential
innovation
The Global Antiviral Drugs Market to Exhibit Growth at a Paltry CAGR of ~4% by 2027 | DelveInsight
Published:
2023-02-02
(Crawled : 16:00)
- prnewswire.com
NVSEF
|
News
|
$93.6375
6.88%
82K
|
Health Technology
|
30.33%
|
O:
-1.71%
H:
0.0%
C:
0.0%
VTRS
|
News
A
|
$11.235
-0.13%
-0.13%
5.1M
|
Health Technology
|
-8.24%
|
O:
-0.16%
H:
0.08%
C:
-0.41%
NVS
|
News
|
$95.12
0.81%
-1.18%
2.4M
|
Health Technology
|
7.41%
|
O:
-1.87%
H:
0.01%
C:
-0.55%
JNJ
|
News
|
$149.12
0.82%
0.0%
9.3M
|
Health Technology
|
-9.58%
|
O:
-1.16%
H:
1.98%
C:
1.56%
BMY
|
$49.14
0.43%
0.0%
7.9M
|
Health Technology
|
-31.01%
|
O:
-1.28%
H:
3.64%
C:
3.48%
ABBV
|
News
|
$167.89
0.89%
0.0%
5.6M
|
Health Technology
|
14.52%
|
O:
-0.46%
H:
0.0%
C:
-0.75%
VIR
|
$8.11
2.01%
1.97%
1.1M
|
Health Technology
|
-72.22%
|
O:
0.62%
H:
2.22%
C:
1.94%
TNXP
|
$0.1579
-1.31%
-1.33%
1.4M
|
Health Technology
|
-97.81%
|
O:
0.85%
H:
5.08%
C:
0.0%
SNY
|
News
|
$47.125
1.78%
1.75%
2.1M
|
Health Technology
|
-4.69%
|
O:
-1.44%
H:
0.0%
C:
0.0%
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
-20.3%
|
O:
-1.95%
H:
0.16%
C:
-1.18%
global
antiviral
growth
market
Global Antiviral Therapeutics Market 2022 to 2027 - Rising Prevalence of Viral Diseases like HIV and Hepatitis Drives Growth
Published:
2023-01-16
(Crawled : 20:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-7.27%
|
O:
-0.2%
H:
0.0%
C:
0.0%
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-45.12%
|
O:
-2.74%
H:
0.43%
C:
-0.99%
JNJ
|
News
|
$149.12
0.82%
0.0%
9.3M
|
Health Technology
|
-14.02%
|
O:
0.33%
H:
0.33%
C:
-0.94%
BMY
|
$49.14
0.43%
0.0%
7.9M
|
Health Technology
|
-32.23%
|
O:
0.83%
H:
0.52%
C:
-1.09%
ABT
|
News
|
$107.07
-0.2%
0.0%
4.9M
|
Health Technology
|
-5.67%
|
O:
-0.01%
H:
0.69%
C:
-0.1%
SNY
|
News
|
$47.125
1.78%
1.75%
2.1M
|
Health Technology
|
-6.1%
|
O:
1.1%
H:
0.22%
C:
0.02%
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
-22.39%
|
O:
-0.26%
H:
0.37%
C:
-0.74%
COCP
|
$1.5299
-1.39%
9.7K
|
Health Technology
|
-28.97%
|
O:
0.47%
H:
11.16%
C:
7.91%
hepatitis
global
antiviral
hiv
therapeutics
growth
market
Antiviral Drugs Market Size To Reach USD 50.02 BN In 2030 Due to Development Of New, Improved, And More Advanced Formulations, Such As Repurposed Drugs And Drug Combination Therapies, Says Reports and Data
Published:
2022-04-13
(Crawled : 15:00)
- prnewswire.com
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
-28.62%
|
O:
1.76%
H:
0.35%
C:
0.35%
NVSEF
|
News
|
$93.6375
6.88%
82K
|
Health Technology
|
24.46%
|
O:
0.45%
H:
0.0%
C:
-0.83%
NVS
|
News
|
$95.12
0.81%
-1.18%
2.4M
|
Health Technology
|
2.27%
|
O:
0.12%
H:
0.44%
C:
0.17%
JNJ
|
News
|
$149.12
0.82%
0.0%
9.3M
|
Health Technology
|
-16.95%
|
O:
0.08%
H:
0.0%
C:
0.0%
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
-13.23%
|
O:
-0.24%
H:
0.45%
C:
0.39%
BMY
|
$49.14
0.43%
0.0%
7.9M
|
Health Technology
|
-35.81%
|
O:
0.24%
H:
0.53%
C:
0.18%
ABBV
|
News
|
$167.89
0.89%
0.0%
5.6M
|
Health Technology
|
0.35%
|
O:
-1.38%
H:
0.0%
C:
-3.67%
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
8.63%
|
O:
-0.02%
H:
0.8%
C:
0.71%
drug
antiviral
repurposed
market
Coronavirus (COVID-19) Current Therapy Market Sees Antiviral Drugs Accounting For A Large Number Of Treatments
Published:
2022-03-15
(Crawled : 16:00)
- prnewswire.com
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
15.13%
|
O:
0.47%
H:
0.62%
C:
-0.18%
covid-19
viral drug
treatment
drug
covid
therapy
antiviral
Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs
Published:
2022-02-08
(Crawled : 17:00)
- biospace.com/
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
4.61%
|
O:
-0.27%
H:
0.81%
C:
-0.2%
research
test
antiviral
Tonix Pharmaceuticals Announces Publication of Paper on Antiviral SARS-CoV-2 Inhibitor, TNX-3500, in JCI Insight
Published:
2021-11-22
(Crawled : 23:00)
- globenewswire.com
TNXP
|
$0.1579
-1.31%
-1.33%
1.4M
|
Health Technology
|
-67.01%
|
O:
15.69%
H:
0.0%
C:
0.0%
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
-4.32%
|
O:
-0.14%
H:
1.43%
C:
1.09%
antiviral
tnx-3500
sars-cov-2
Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021
Published:
2021-09-20
(Crawled : 13:00)
- biospace.com/
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
-5.48%
|
O:
0.14%
H:
1.4%
C:
0.04%
disease
infectious disease
test
antiviral
research
$76.28 Billion Anti-Viral Therapies Market, 2027 - Growing Emphasis on Launching Anti-Viral Agents
Published:
2021-03-16
(Crawled : 11:00)
- prnewswire.com
JNJ
|
News
|
$149.12
0.82%
0.0%
9.3M
|
Health Technology
|
-7.04%
|
O:
0.02%
H:
0.76%
C:
0.57%
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
13.13%
|
O:
0.08%
H:
1.42%
C:
1.23%
BMY
|
$49.14
0.43%
0.0%
7.9M
|
Health Technology
|
-19.95%
|
O:
-0.08%
H:
1.3%
C:
0.91%
ABBV
|
News
|
$167.89
0.89%
0.0%
5.6M
|
Health Technology
|
52.27%
|
O:
-0.28%
H:
1.03%
C:
0.81%
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
6.15%
|
O:
0.27%
H:
1.52%
C:
1.22%
growing
therapy
antiviral
Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology
Published:
2020-12-07
(Crawled : 12:00)
- globenewswire.com
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
8.76%
|
O:
0.17%
H:
0.06%
C:
-1.35%
MTNB
|
$0.18
-4.1%
0.44%
1.4M
|
Health Technology
|
-83.49%
|
O:
10.09%
H:
4.17%
C:
-7.5%
biopharma
collaboration
disease
announces collaboration
liver
infectious disease
antiviral
Gainers vs Losers
75%
25%
Top 10 Gainers
MTTR
|
News
M
|
$4.78
174.71%
63.6%
72M
|
AGBA
|
$2.565
105.2%
51.27%
200M
|
Finance
MLEC
|
$2.44
74.29%
42.62%
78M
|
n/a
EDBL
|
News
|
$6.28
67.02%
40.13%
16M
|
ATGL
|
$2.91
48.81%
32.8%
180K
|
ZAPP
|
$0.2175
47.16%
32.05%
16M
|
n/a
ONFO
|
$0.6075
38.38%
27.74%
7.3M
|
n/a
VIVK
|
$1.48
38.32%
27.7%
530K
|
Professional, Scientific, and T...
MNTS
|
$0.5
35.69%
26.3%
4.8M
|
SDIG
A
|
$3.635
35.13%
26.0%
1M
|
Your saved searches
Save your searches and get alerts when important news are released.